Dr Reddys Laboratories Ltd (RDY) SEC Filing 6-K Foreign Issuer Report for the period ending Tuesday, December 6, 2022

Dr Reddys Laboratories Ltd

CIK: 1135951 Ticker: RDY

View differences made from one to another to evaluate Dr Reddys Laboratories Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dr Reddys Laboratories Ltd.


Assess how Dr Reddys Laboratories Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dr Reddys Laboratories Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Dr Reddys Laboratories Ltd provided additional information to their SEC Filing as exhibits

Ticker: RDY
CIK: 1135951
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001575872-22-001269
Submitted to the SEC: Tue Dec 06 2022 9:19:03 PM EST
Accepted by the SEC: Wed Dec 07 2022
Period: Tuesday, December 6, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: